Advertisement

Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept

  • Cristina Calvo-GonzalezEmail author
  • Juan Reche-Frutos
  • José Ignacio Fernández-Vigo
  • Juan Donate-López
  • Irene Serrano-García
  • Cristina Fernández-Pérez
Original Paper
  • 89 Downloads

Abstract

Purpose

To describe indocyanine green angiography (ICGA) and visual acuity (VA) results in patients with neovascular age-related macular degeneration (nAMD) refractory to ranibizumab switched to aflibercept.

Methods

This study is a prospective interventional case series. Thirty-two eyes of 32 patients with nAMD showing a poor response after at least 24 months of ranibizumab were switched to aflibercept. Twenty eyes had type I choroidal neovascularization (CNV group), and 12 eyes had polypoidal choroidal vasculopathy (PCV group). After an initial loading dose of three monthly aflibercept injections, treatment was continued on a treat-and-extend basis. ICGA was performed just before the first aflibercept injection (baseline) and 12 and 24 months later. The variables recorded were: closure of polyps and lesion area, VA, number of aflibercept injections, dry macula, and pigment epithelium detachment.

Results

The following means were recorded in the CNV and PCV groups, respectively: number of ranibizumab injections 20.4 ± 11.2 and 22.4 ± 12.9 (p = 0.740); baseline VA (before aflibercept) 73.2 ± 9.1 and 70.3 ± 13.7 letters (p = 0.654); and final VA 73.0 ± 7.6 and 69.3 ± 15.6 letters (p = 0.509). VA remained stable (p = 0.761 and 0.964) after 15.5 ± 3 and 15.1 ± 3.5 aflibercept injections (p = 0.244). At 24 months, dry macula was noted in 40 to 50% of the eyes (p = 0.620). Complete resolution of polyps was observed in 58% at 12 months and 92% at 24 months.

Conclusions

In patients with nAMD refractory to ranibizumab, aflibercept was effective at maintaining VA and closing numerous polyps. In half of the patients, dry macula was observed at 24 months.

Keywords

Indocyanine green angiography Polypoidal choroidal vasculopathy Age-related macular degeneration Ranibizumab Poor responders Aflibercept 

Notes

Compliance with ethical standards

Conflicts of interest

There are no known conflicts of interest by the authors associated with this publication.

References

  1. 1.
    Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116CrossRefGoogle Scholar
  2. 2.
    Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG (2016) Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res 53:107–139CrossRefGoogle Scholar
  3. 3.
    Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728–1738CrossRefGoogle Scholar
  4. 4.
    Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, Barthelmes D, Gillies MC (2018) Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res 65:127–146CrossRefGoogle Scholar
  5. 5.
    Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA (1997) The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 115:478–485CrossRefGoogle Scholar
  6. 6.
    Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A et al (2013) Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 33:686–716CrossRefGoogle Scholar
  7. 7.
    Cho M, Barbazetto IA, Freund KB (2009) Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 148:70–78CrossRefGoogle Scholar
  8. 8.
    Stangos AN, Gandhi JS, Nair-Sahni J, Heimann H, Pournaras CJ, Harding SP (2010) Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 150:666–673CrossRefGoogle Scholar
  9. 9.
    Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N (2015) Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 253:1471–1477CrossRefGoogle Scholar
  10. 10.
    Patel KH, Chow CC, Rathod R, MielerWF LJ, Ulanski LJ, Leiderman YI, Arun V, Chau FY (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 27:663–667CrossRefGoogle Scholar
  11. 11.
    Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612CrossRefGoogle Scholar
  12. 12.
    Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156(15–22):e11Google Scholar
  13. 13.
    Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M (2014) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 121:188–192CrossRefGoogle Scholar
  14. 14.
    Hara C, Sawa M, Sayanagi K, Nishida K (2016) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Retina 36(1):37–45CrossRefGoogle Scholar
  15. 15.
    Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, Sekiryu T, Iida T (2015) One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122:1866–1872CrossRefGoogle Scholar
  16. 16.
    Hosokawa M, Morizane Y, Hirano M, Kimura S, Kumase F, Shiode Y, Doi S, Toshima S, Hosogi M, Fujiwara A, Mitsuhashi T, Shiraga F (2017) One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 61:150–158CrossRefGoogle Scholar
  17. 17.
    Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T et al (2017) One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: the APOLLO study. Ophthalmologica 238:163–171CrossRefGoogle Scholar
  18. 18.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J et al (2016) Prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. BMC Ophthalmol 16:127CrossRefGoogle Scholar
  19. 19.
    Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453–1464CrossRefGoogle Scholar
  20. 20.
    Wolff B, Vasseur V, Cahuzac A, Coscas F, Castelnovo L, Favard C, Michel G, Français C, Salomon L, Mauget-Faÿsse M (2018) Aflibercept treatment in polypoidal choroidal vasculopathy: results of a prospective study in a Caucasian population. Ophthalmologica 25:1–5Google Scholar
  21. 21.
    Takayama K, Kaneko H, Kataoka K, Hattori K, Ra E, Tsunekawa T et al (2017) Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: retrospective observation study. PLoS ONE 12:e0176100CrossRefGoogle Scholar
  22. 22.
    Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H et al (2017) One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:541–548CrossRefGoogle Scholar
  23. 23.
    Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB et al (2018) Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125:708–724CrossRefGoogle Scholar
  24. 24.
    Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R (2007) Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 27:589–594CrossRefGoogle Scholar
  25. 25.
    Ozkaya A, Alagoz C, Garip R, Alkin Z, Perente I, Yazici AT, Taskapili M (2016) The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting. Eye (Lond) 30(7):958–965CrossRefGoogle Scholar
  26. 26.
    Hatz K, Prünte C (2014) Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol 98:188–194CrossRefGoogle Scholar
  27. 27.
    Agorogiannis EI, Pearce IA, Yadav S, Parry DG, Beare NAV (2018) Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy. Eye (Lond).  https://doi.org/10.1038/s41433-018-0168-2 Google Scholar
  28. 28.
    Freund KB, Korobelnik J-F, Devenyi R, Framme C, Galic J, Herbert E et al (2015) Treat- and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489–1506CrossRefGoogle Scholar
  29. 29.
    Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L et al (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration. Ophthalmology 122:2514–2522CrossRefGoogle Scholar
  30. 30.
    Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE, VAULT Study Group (2017) Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol 255:493–502CrossRefGoogle Scholar
  31. 31.
    Medina-Baena M, Huertos-Carrillo MJ, Rodríguez L, García-Pulido JI, Cornejo-Castillo C, Calandria-Amiguetti JM (2018) One-year outcome of aflibercept and photodynamic therapy in a caucasian patient with polypoidal choroidal vasculopathy refractory to ranibizumab and photodynamic therapy. Case Rep Ophthalmol 9:172–178CrossRefGoogle Scholar
  32. 32.
    Hara C, Wakabayashi T, Toyama H, Fukushima Y, Sayanagi K, Sato S, Sakaguchi H, Nishida K (2018) Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept. Br J Ophthalmol 8:8–9.  https://doi.org/10.1136/bjophthalmol-2018-312275 Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Cristina Calvo-Gonzalez
    • 1
    Email author
  • Juan Reche-Frutos
    • 1
  • José Ignacio Fernández-Vigo
    • 1
  • Juan Donate-López
    • 1
  • Irene Serrano-García
    • 2
  • Cristina Fernández-Pérez
    • 2
  1. 1.Department of OphthalmologyHospital Universitario Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC)MadridSpain
  2. 2.Department of Preventive MedicineHospital Universitario Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC)MadridSpain

Personalised recommendations